Table 1.
Patient Characteristics of Included Cohort and Cohort with MRI Morphological Reading
| Cohort with Sphericity (n = 935) | Cohort with Morphologic Pattern (n = 220) | P-Value | |
|---|---|---|---|
| Agea | 49 ± 10 | 49 ± 11 | .890 |
| HR/HER2 Subtype | |||
| HR+/HER2− | 365 (39%) | 77 (35.0%) | .650b |
| HR+/HER2+ | 148 (16%) | 40 (18.2%) | |
| HR−/HER2+ | 80 (9%) | 18 (8.2%) | |
| HR−/HER2− | 342 (37%) | 85 (38.6%) | |
| Menopausal Status | |||
| Premenopausal | 442 (47%) | 105 (47.7%) | .044b |
| Perimenopausal | 32 (3%) | 1 (0.5%) | |
| Postmenopausal | 271 (29%) | 74 (33.6%) | |
| Not applicable | 125 (13%) | 22 (10%) | |
| Unknown | 65 (7%) | 18 (8.2%) | |
| SPH at T0a | 0.22 ± 0.099 | 0.22 ± 0.095 | .890 |
| pCR Outcome | |||
| 0: non-pCR | 625 (67%) | 143 (65%) | .630b |
| 1: pCR | 310 (33%) | 77 (35%) | |
Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2; SP, sphericity.
a Values of age and SPH at T0 are mean ± standard deviation.
b Estimated by Fisher exact test.